Last reviewed · How we verify

IDA - Ivermectin + DEC + albendazole

Medicines Development for Global Health · Phase 3 active Small molecule

IDA - Ivermectin + DEC + albendazole is a Antiparasitic combination Small molecule drug developed by Medicines Development for Global Health. It is currently in Phase 3 development for Lymphatic filariasis (mass drug administration), Onchocerciasis (river blindness), Co-infections with multiple helminth and filarial species.

IDA is a triple-drug combination that paralyzes and kills parasitic worms through multiple mechanisms: ivermectin and DEC (diethylcarbamazine) target neuromuscular function in microfilariae, while albendazole disrupts microtubule formation in helminths.

IDA is a triple-drug combination that paralyzes and kills parasitic worms through multiple mechanisms: ivermectin and DEC (diethylcarbamazine) target neuromuscular function in microfilariae, while albendazole disrupts microtubule formation in helminths. Used for Lymphatic filariasis (mass drug administration), Onchocerciasis (river blindness), Co-infections with multiple helminth and filarial species.

At a glance

Generic nameIDA - Ivermectin + DEC + albendazole
SponsorMedicines Development for Global Health
Drug classAntiparasitic combination
TargetGABA-gated chloride channels (ivermectin); β-tubulin (albendazole); microfilarial motility (DEC)
ModalitySmall molecule
Therapeutic areaInfectious Disease / Parasitology
PhasePhase 3

Mechanism of action

Ivermectin acts as a GABA-gated chloride channel agonist, causing paralysis in nematodes and arthropods. DEC immobilizes microfilariae and enhances immune-mediated clearance. Albendazole inhibits β-tubulin polymerization, disrupting microtubule assembly essential for parasite survival. The combination targets multiple parasite species and life stages simultaneously.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about IDA - Ivermectin + DEC + albendazole

What is IDA - Ivermectin + DEC + albendazole?

IDA - Ivermectin + DEC + albendazole is a Antiparasitic combination drug developed by Medicines Development for Global Health, indicated for Lymphatic filariasis (mass drug administration), Onchocerciasis (river blindness), Co-infections with multiple helminth and filarial species.

How does IDA - Ivermectin + DEC + albendazole work?

IDA is a triple-drug combination that paralyzes and kills parasitic worms through multiple mechanisms: ivermectin and DEC (diethylcarbamazine) target neuromuscular function in microfilariae, while albendazole disrupts microtubule formation in helminths.

What is IDA - Ivermectin + DEC + albendazole used for?

IDA - Ivermectin + DEC + albendazole is indicated for Lymphatic filariasis (mass drug administration), Onchocerciasis (river blindness), Co-infections with multiple helminth and filarial species.

Who makes IDA - Ivermectin + DEC + albendazole?

IDA - Ivermectin + DEC + albendazole is developed by Medicines Development for Global Health (see full Medicines Development for Global Health pipeline at /company/medicines-development-for-global-health).

What drug class is IDA - Ivermectin + DEC + albendazole in?

IDA - Ivermectin + DEC + albendazole belongs to the Antiparasitic combination class. See all Antiparasitic combination drugs at /class/antiparasitic-combination.

What development phase is IDA - Ivermectin + DEC + albendazole in?

IDA - Ivermectin + DEC + albendazole is in Phase 3.

What are the side effects of IDA - Ivermectin + DEC + albendazole?

Common side effects of IDA - Ivermectin + DEC + albendazole include Headache, Fever, Pruritus, Gastrointestinal disturbance (nausea, diarrhea), Lymphadenitis (from parasite death), Arthralgia/myalgia.

What does IDA - Ivermectin + DEC + albendazole target?

IDA - Ivermectin + DEC + albendazole targets GABA-gated chloride channels (ivermectin); β-tubulin (albendazole); microfilarial motility (DEC) and is a Antiparasitic combination.

Related